Review Article

Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders

Debora Martorelli,1 Elena Muraro,1 Anna Merlo,2 Riccardo Turrini,2 Damiana Antonia Faè,1 Antonio Rosato,2 and Riccardo Dolcetti1,3

1 Cancer Bioimmunotherapy Unit CRO-IRCCS, National Cancer Institute, Via F. Gallini 2, 33081 Aviano, Italy
2 Department of Oncology and Surgical Sciences, University of Padova, Via F. Gallini 2, 35128 Padova, Italy
3 Cancer Bioimmunotherapy Unit, Department of Medical Oncology, CRO National Cancer Institute, Via F. Gallini 2, 33081 Aviano, Italy

Correspondence should be addressed to Riccardo Dolcetti, rdolcetti@cro.it

Received 27 July 2011; Revised 28 September 2011; Accepted 16 October 2011

Academic Editor: Mauro Tognon

Copyright © 2012 Debora Martorelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The recent demonstration that immunotherapeutic approaches may be clinically effective for cancer patients has renewed the interest for this strategy of intervention. In particular, clinical trials using adoptive T-cell therapies disclosed encouraging results, particularly in the context of Epstein-Barr-virus- (EBV-) related tumors. Nevertheless, the rate of complete clinical responses is still limited, thus stimulating the development of more effective therapeutic protocols. Considering the relevance of innate immunity in controlling both infections and cancers, innovative immunotherapeutic approaches should take into account also this compartment to improve clinical efficacy. Evidence accumulated so far indicates that innate immunity effectors, particularly NK cells, can be exploited with therapeutic purposes and new targets have been recently identified. We herein review the complex interactions between EBV and innate immunity and summarize the therapeutic strategies involving both adaptive and innate immune system, in the light of a fruitful integration between these immunotherapeutic modalities for a better control of EBV-driven tumors.

1. Introduction

An increasing number of clinical trials involving cell-based immunotherapies is ongoing for the prevention and treatment of different types of human cancers [1–3]. These therapeutic approaches involve two different modalities: active cellular immunotherapies, that rely on autologous dendritic cells or other antigen presenting cells [4, 5] and adoptive T-cell therapies (ACT), in which the ex vivo activation, expansion, and subsequent reinfusion of tumor-reactive T cells hopefully result in attack and elimination of tumors [6–8]. Nevertheless, due to its complexity and costs ACT can be performed only by a limited number of specialized centers and it is still challenging to adapt this treatment for a broader use. Perhaps one of the best studied ACT approaches is constituted by the adoptive immunotherapy of EBV-associated malignancies.

The Epstein-Barr Virus (EBV) is a double-stranded DNA virus, a member of the gamma herpes virus family and has a genome comprising approximately 172 kb pairs. Over 70 open reading frames allow for the transcription of genes for a large number of different viral proteins. Expression of different combinations of these proteins allows the virus to establish different forms of infection. Thus, in lytic infection, the virus expresses the full complement of immediate early, early, and late lytic cycle proteins and is capable of replicating within the host cell. In latent infection, the virus expresses a smaller number of proteins and does not replicate but is able to persist within the host cell. Four latency types have been described depending on which of these latent genes are
expressed, as shown in Figure 1. Long-lived EBV-carrying memory B lymphocytes may express a putative Latency 0, characterized by complete silencing of the viral genome, or a Latency I, in which LMP-2A alone or together with EBNA-1 may be expressed [9]. The expression of these viral proteins is crucial for establishing and maintaining EBV persistence in memory B lymphocytes. An intermediate form of latency (Latency II) has been identified in B-lymphocytes homing to the germinal centers of lymphoid follicles [10]. In these cells, the expression of EBV proteins is restricted to EBNA-1 and the LMPs (LMP-1, -2A, and -2B), a “rescue” program that provides signals allowing infected lymphoblasts to survive and differentiate into memory B cells. In the absence of effective immune surveillance, as observed in *in vitro* or *in vivo* in immune suppressed patients, EBV-infected B lymphocytes show a different latency program, called Latency III, characterized by the expression of the six EBV nuclear antigens (EBNA1-6) and the three LMPs [11]. During latency, EBV also expresses two small noncoding RNAs, known as EBER1 and EBER2 (167 and 172 nucleotides, resp.), the most abundant RNAs in EBV-infected cells [12]. Furthermore, a growing body of data indicates that viruses, including EBV, exploit the cellular microRNA (miRNA) machinery to modulate and/or subvert virus-host cell interactions [13–15]. miRNAs are 19- to 25-nucleotide-long single-stranded RNAs processed from transcripts with stem-loop structures [16] and endowed with diverse functions, including the regulation of cellular differentiation, proliferation, and apoptosis [17–19]. miRNAs might also function as tumor suppressors [20] or oncogenes [20, 21].

Primary EBV infection mainly takes place in the oropharyngeal region to which the virus is conveyed by saliva droplets from infected individuals [22]. The nature of the target cells in the oral mucosa is still controversial, but there is agreement that B cells are infected at some stage of the process. If infection is delayed to adolescence or adulthood, it can cause infectious mononucleosis (IM), a self-resolving lymphoid disorder largely resulting from an uncontrolled T-cell reaction directed against EBV-infected cells. In IM patients, EBV is exclusively found in B blasts that undergo continuous proliferation under the influence of all latent genes (Latency III). Following resolution of primary infection, EBV establishes a lifelong persistence in memory B cells where the virus usually remains clinically silent. In this B-cell
viral expression is entirely repressed, a process described as a “True Latency.” The pleiotropic nature of EBV target cells in vivo, including B and T lymphocytes, NK cells, squamous and glandular epithelia, and smooth muscle cells, demonstrates that the virus possesses the ability to infect a large spectrum of different cell types [23].

2. EBV-Associated Diseases

2.1. Infectious Mononucleosis. EBV is one of a variety of infectious agents that can induce an infectious mononucleosis syndrome. IM may be misdiagnosed as a high-grade large B-cell lymphoma, or even Hodgkin’s lymphoma, particularly in cases containing a large number of B immunoblasts, some of which express CD30, and rare Reed-Sternberg like cells [24]. EBV-infected B-cells in IM show a typical Latency III expression pattern including EBERs, EBNA1, EBNA2, and LMP1, which renders virus detection very easy. However, the mere presence of EBV does not exclude a large B cell lymphoma, but detection of EBNA2 expression in infected cells strongly suggests the diagnosis of IM.

2.2. EBV-Associated Tumors in Immunosuppressed Individuals. The role of the immune system in controlling EBV latent infection is best illustrated by the observation that individuals with a congenital or acquired (e.g., after HIV infection or organ transplantation) immune deficiency are at increased risk to develop EBV-associated diseases, whose histological type varies according to the type and the severity of immunodeficiency. In these cases, the clinical context is more suggestive for the diagnosis of this category of tumors than the detection of EBV alone [25]. Accordingly, considering that the pattern of EBV latent gene expression may also vary concomitantly with cytomorphological changes [26], the assessment of viral status can have important consequences for the treatment of these lymphomas, as EBV-positive lesions are in principle amenable to EBV-specific T-cell therapy or even to antiviral therapy.

2.2.1. Posttransplant Lymphoproliferative Disorders. Post-transplant lymphoproliferative disorder (PTLD) is thought to result from iatrogenic immune suppression and chronic antigenic stimulation from the engrafted organ after hematopoietic stem cell (HSC) or solid organ transplantation (SOT). PTLD includes a wide spectrum of diseases ranging from polyclonal reactive lymphoid hyperplasia to monoclonal malignant lymphoma. About 80% of PTLDs are associated with EBV and its overall incidence is about 1% in patients with hematopoietic cell transplantation and less than 2% in those with solid-organ transplantation. PTLD is more common in pediatric patients, largely because children are more likely to be primarily infected with EBV via the graft and the risk of developing PTLD is greatest during the first year after transplantation and declines thereafter [27]. After hematopoietic cell transplantation, this disease may involve nodal and extranodal sites, while PTLD after solid-organ transplantation frequently involves the allograft itself, which suggests a lymphomagenic role of chronic antigen stimulation occurring within the graft [28]. Other sites are also frequently involved, such as the gastrointestinal tract, liver, lungs, lymph nodes, bone marrow, skin, and central nervous system. Interestingly, PTLD occurring in the setting of primary EBV infection or associated with use of the immunosuppressive OKT3 antibody is often seen very early after the transplant in heart, kidney, and pancreas allograft recipients [29, 30]. Moreover, the reduction of pharmacologic load of immunosuppressive drugs may also lower the incidence of PTLD, by restoring EBV-specific immunity, provided that the risk of acute rejection of the allograft is closely monitored [31]. Finally, chemotherapy and anti-B-cell antibodies may be used in combination with the reduction in immune suppression, whereas surgery may be considered for localized PTLDs. Reduction of immune suppression alone results in clinical remission in 25–63% of adult and in 40–86% of pediatric PTLD patients [27].

2.2.2. HIV-Associated Lymphomas. Patients with HIV infection are at 60 to 200-fold increased risk of developing various lymphomas, considered as the first acquired-immunodeficiency-syndrome-(AIDS-) defining illness in 3–5% of HIV+ patients [25]. EBV positivity is significantly correlated with HIV disease status and subtypes of HIV-associated lymphoma, generally involving extranodal tissues, in particular the gastrointestinal tract, lungs, liver, CNS, and bone marrow. The overall incidence of EBV-positive cells in HIV-related lymphomas is about 60%, even if the incidence varies with the site and subtype of lymphoma.

2.3. EBV and Hematological Malignancies. EBV infection has been associated with several hematopoietic cell tumors.

2.3.1. B-Cell Lymphomas. Systematic testing of a large panel of B-cell lymphomas has shown that the EBV genome is found mainly in high-grade lymphomas, though rare cases of partial EBV infection of low-grade B-cell lymphomas have been observed [32].

Burkitt Lymphoma (BL). Burkitt lymphoma was first described in children from equatorial Africa by Denis Burkitt in 1958. It is a highly proliferative B-cell tumor that includes 3 variants: endemic (affecting children in equatorial Africa and New Guinea), sporadic (children and young adults throughout the world), and immunodeficiency-related (primarily in association with HIV infection) [33]. EBV has been detected in virtually all cases of the endemic variant, in 15–20% of the sporadic variant, and in 30–40% of the immunodeficiency-related variant [34]. In all variants, irrespective of the EBV status, constitutive activation of the c-myc oncogene through its translocation into one of the immunoglobulin loci is the key factor in the oncogenesis of BL [33, 34]. The detection of somatic hypermutations in the V region of the immunoglobulin genes and the phenotype of Burkitt lymphoma cells indicate a germinal center cell origin of this lymphoma [35]. Most EBV-positive cases exhibit a highly restricted pattern of expression of latent gene products, including only EBNA1 and the EBERs (Latency I). However, it has been recently
Inflammatory Pseudotumor-Like Follicular Dendritic Cell Tumor (IPLFD). IPLFD preferentially develops in liver and spleen, or more rarely in lymph nodes. This exceptional tumor is characterized by a prominent inflammatory background including numerous lymphocytes and plasma cells, among which neoplastic follicular dendritic cells (FDCs) can be identified [52]. Viral infection is readily established with an EBER assay showing intense signals in all cancer cells; LMP1 staining, although consistently positive, is generally weak. Due to the consistent association with EBV, diagnosis of this entity requires detection of the virus.
2.4. EBV and Nasopharyngeal Carcinoma (NPC). Nasopharyngeal carcinoma is classified as a malignant neoplasm arising from the mucosal epithelium of the nasopharynx, most often within the lateral nasopharyngeal recess or fossa of Rosenmüller. There are three histopathologic subtypes of NPC: a well-differentiated keratinizing type, a moderately-differentiated, nonkeratinizing type, and an undifferentiated type, which typically contains large numbers of noncancerous chronic inflammatory lymphocytes. The undifferentiated form is the most common and also the most strongly associated with EBV infection. NPCs are rare in most countries, especially in Europe and North America (incidence below 1/100,000), whereas it has a high incidence in several areas in Southern China, especially in the Cantonese region around Guangzhou, where the incidence is approximately of 30–80/100,000 cases per year and where the diet probably plays a carcinogenic role. EBV is strongly associated with undifferentiated nasopharyngeal carcinomas, in which virus infection is observed virtually in 100% of the cases [53], and epithelial EBV infection is also well documented in vitro [54]. Accordingly, following primary infection in the oropharynx, EBV persists in numerous anatomical sites including pharyngeal tonsils, adenoids, lymph nodes, and peripheral blood, where the virus is present in small resting memory B cells with latent gene expression being virtually absent or limited to EBER, LMP2a, and EBNA1 [55]. Despite available evidence, the presence of EBV within normal epithelial cells in vivo remains a matter of debate. Some authors demonstrated the presence of EBV in desquamated squamous and tonsillar epithelium [56, 57]. In contrast, other studies have reported no virus in the same cells or unequivocal evidence of EBV-infected tonsillar epithelial cells by EBER ISH and/or LMP1 immunostaining [58–60]. Although the demonstration of virus latency and replication in vivo is still under investigation, it is well known that vigorous humoral and cellular immune responses control the proliferation of EBV-infected cells in healthy virus carriers [61, 62]. Early after the discovery of EBV association with NPC, a deregulation of the EBV-specific immune response with elevated IgA titers against the virus was noted [63]. This indicated that the immune response at the site of tumor development was abnormal, and that the tumor might influence its microenvironment to facilitate neoplastic cell growth. Accordingly, recent studies supported the notion that local immune suppression rather than a systemic deficiency in EBV-specific immune control may contribute to NPC development. Indeed, both nonspecific (NK-cell-mediated) and EBV-specific (T-cell-mediated) responses were shown to play important roles during primary infection, while EBV-specific T-cells appear to be critically involved in restraining the proliferation of EBV infected cells during life-long persistent infection. On these grounds, some studies confirmed that EBV-specific T cells are maintained in healthy carriers at relatively high frequencies throughout life [64], whereas EBV-specific CD4+ and CD8+ responses might be reactivated from peripheral blood of NPC patients [65, 66]. In particular, clinical and immunologic responses were observed by Comoli et al. after EBV-targeting CTL therapy in patients with radiotherapy- and chemotherapy-resistant stage IV NPCs [67]. Importantly, they confirmed that, despite immuno-suppressive treatments, it is possible to reactivate and expand ex vivo these effectors, suggesting that reconstitution of EBV-specific immunity could also be a useful strategy in the management of NPC. Interestingly, a significant immune suppression can also be observed at the tumor site. Indeed, even though LMP1- and LMP2-specific CTLs were enriched in tumor infiltrating lymphocytes, their cytotoxicity and cytokine secretion could be impaired, resulting in a local immunomodulation. Particularly, the high presence of natural Tregs (CD4+CD25+FoxP3+) [68] and the production of galectin-9-carrying exosomes in NPC patients [69] could suppress EBV-specific immune responses in tumor tissues. In addition to active T cell suppression at the tumor site, the expression of immune suppressive cytokines, such as interleukin 10 (IL-10), has also been related with an immune escape mechanism, partly because EBV-encoded LMP1 can induce IL-10 [70]. However, the importance of immune suppressive cytokines seems limited in NPC [71]. In addition, the efficiency with which NPC can present antigens to T-cells might also be compromised. While earlier studies based on a limited number of NPC cell lines suggested that antigen processing for MHC-I presentation was intact in NPC cells [72], a more recent study on primary tumor tissues suggested that the MHC-I antigen processing machinery is downregulated in the majority of tumors [73]. Together, these data suggest that NPC cells impair EBV-specific immune control locally, while allowing efficient systemic immune responses against this virus.

3. EBV Infection and the Immune System

The immune system preserves the integrity of its host by recognizing and resisting invaders; the frequency and severity of EBV-associated diseases, particularly in immunocompromised individuals, highlight the critical importance of immune responses in controlling this virus infection. It is well known that the adaptive arm of the immune system plays a pivotal role in protective immunity against EBV [74, 75]. Nevertheless, emerging data suggest that also the innate compartment may cooperate to the immune response [76–78], mounting a highly coordinated cascade of molecular interactions, which not only activate but also heighten the potential to bias the ensuing adaptive phenotype. Since the role of the innate immunity in EBV infection is still unclear, our aim is to mainly review current knowledge in this respect, with a particular focus on the contribution of innate immune cells in controlling the progression of virus infection towards the oncogenic phenotype.

3.1. Innate Immunity and EBV Infection. Understanding the importance of host innate immune responses in the context of EBV infection will allow a better understanding of how EBV can persist in the infected host to promote cell transformation [79]. Intriguingly, EBV interacts with different cell types that are crucial mediators of innate immune responses (Figure 1), including NK cells, neutrophils, and monocytes/macrophages. Moreover, the virus can also infect epithelial
3.1.1. NK Cells. NK cells are innate lymphocytes that play a pivotal role in the control of infections and in the immune surveillance against transformed cells [80]. In particular, early after primary viral infections NK cells are thought to limit the viral burden until virus-specific T cells are able to eliminate the infection or control viral titers at low levels. Notably, NK cells produce cytokines such as interferon-y (IFN-γ), proliferate, and increase their cytotoxicity upon activation by both myeloid and plasmacytoid dendritic cells (DCs) [81]. Therefore, DCs seem to activate NK cells early after infection in order to restrict pathogen replication until the adaptive immune system establishes long-lasting immune control. Two main functional NK cell subsets have been distinguished in humans: CD16<sup>+</sup>CD56<sup>dim</sup> NK cells, which readily lyse susceptible target cells, but secrete only low levels of cytokines after activation; and CD16<sup>−</sup>CD56<sup>bright</sup> NK cells that produce large amounts of cytokines upon stimulation and acquire cytotoxicity only after prolonged activation [82]. CD16<sup>−</sup>CD56<sup>dim</sup> cells constitute about 90% of human circulating NK cells, whereas CD16<sup>−</sup>CD56<sup>bright</sup> NK cells represent <10% of the peripheral blood NK cell pool. However, in secondary lymphoid organs such as tonsils and lymph nodes, the CD16<sup>−</sup>CD56<sup>bright</sup> NK cells are the dominant subset [83]. Interestingly, viral double-stranded RNA (dsRNA) products, including EBV convergent transcription of LMP1 and LMP2 RNA and EBERs dsRNA stem-loop structures [84], trigger monocyte toll-like receptors (TLRs) inducing maturation of DCs, which through the production of high levels of IL-12, activate CD16<sup>−</sup>CD56<sup>bright</sup> NK cells more efficiently than other mature DC preparations [85]. Because the tonsils are the primary site of EBV infection, the DC-NK cell crosstalk could trigger NK cells to limit B cell transformation during EBV infection (Figure 1). Indeed, in vitro virus-activated DCs elicit 50-fold stronger IFN-γ secretion from tonsil NK cells than from peripheral blood NK cells; these high IFN-γ concentrations delayed latent EBV antigen expression, inhibit B-cells transformation, and decrease their proliferation during the first week after EBV infection in vitro [86]. In addition to its direct antiviral activity, IFN-γ secreted by DC-activated NK cells might also shape the EBV-specific adaptive immune response by favouring a Th1-polarization (Figure 1), which is observed in EBV-positive individuals. These in vitro findings suggest that humans have a strategically well-positioned population of NK cells, which directly hampers pathogen entry at mucosal sites and might restrict EBV infection until adaptive immunity establishes immune control of this persistent and oncogenic human pathogen [86]. However, only few in vivo examples support this hypothesis [85], and little is known about NK cell contribution to EBV persistence, thus still leaving several open questions.

In addition to protective T-cell immunity in healthy virus carriers, several lines of evidence suggest a role for innate lymphocytes in the resistance against EBV-associated malignancies. For example, in male patients with X-linked lymphoproliferative disease (XLP), who frequently succumb after primary EBV infection as a consequence of EBV-driven lymphomas, a mutation in the SAP (signalling-lymphocyte activation-molecule-(SLAM)-associated protein) gene leads to defective recognition of EBV-transformed B cells by T and NK cells [87]. Although the biologic effects of SAP mutations are not limited to alterations in NK cell function, this defective recognition most likely contributes to loss of EBV specific immune control. Furthermore, during EBV latency, the virus develops several mechanisms of immune-escape from this innate immunity cell subset, including the inhibition of NK cells activation through Epstein-Barr-virus-induced gene 3 (EBI3). EBV-transformed B-lymphocytes express at high levels the EBI3 protein, which is related to the p40 subunit of IL-12 and associates with p35 and, consistent with a potential immunosuppressive activity, a peptide derived from EBI3 has been shown to bind HLA-G, which is the ligand of inhibitory receptors expressed on NK cells and CTLs [78, 88]. Moreover, in situ analysis revealed EBI3 overexpression in neoplastic cells of individuals affected by HLs and LMP1-positive EBV-associated lymphoproliferative disorders (including posttransplant LPDs and nasal-type NK/T-cell lymphomas) [89], thus supporting its hypothetical role in regulating immune response against EBV. Finally, NK cells seem to play a fundamental role in T-cell-depleted HLA-haploidentical HSCT (hematopoietic stem cell transplantation), indeed in the early posttransplant period, lymphocytes in the peripheral blood are mostly NK cell populations and the antileukemia effect is mediated by “alloreactive” (i.e., KIR/HLA-mismatched) NK cells originated from donor HSCs [90]. Nevertheless, in these patients an increase in EBV load is often observed, until they receive donor EBV-specific cytotoxic T-lymphocytes, suggesting that in this setting NK cells are not able to control EBV DNAemia [91].

3.1.2. Phagocytes. In addition to the clearance of virions or virally infected cells by phagocytosis, both neutrophils and monocytes elicit a respiratory burst when exposed to viruses and can produce a variety of mediators, some of which have antiviral activity [92]. Moreover, EBV genome was detected in non-B-cells, including phagocytes, of most patients with EBV-lymphoproliferative disorders [93]. Interestingly, monocytes and macrophages are involved in the uptake of small vesicles called exosomes, containing viral miRNA. Exosomes are nanosized membrane vesicles released from a wide variety of cells that have immune stimulatory, inhibitory, or tolerance-inducing effects, depending on their cellular origin [94]. Exosome secretion protects miRNA by RNases degradation, thus miRNA secreted by EBV-infected cells are transferred to uninfected cells and could act also in EBV recipients [95]. It has been demonstrated that exosomes of different origin and with function can selectively target different immune cells in vitro. In this regard, while exosomes derived from EBV-transformed lymphoblastoid B-cell lines target preferentially B cells, DC-derived exosomes are mainly associated with monocytes, which actively engulf these vesicles [94]. Thus, exosomes play a role during the early phases of EBV infection, also involving innate immunity-related cell types, that otherwise would not be directly targeted by the
Neutrophils. As in the case of most viral infections, a blood neutrophil increase is observed during the initial phases of EBV infection, whereas a transient episode of acute neutropenia is often seen in IM patients during the third and fourth weeks of illness [96–98]. In vitro studies showed that the interaction of EBV with these cells causes an abortive infection, where the virus penetrates the cells and is transported to the nucleus, even if this is not followed by gene expression. Infected neutrophils rapidly die by apoptosis, probably via Fas triggering by its ligand that is upregulated upon EBV infection [99]. EBV particles can bind to 30% of neutrophils, although these cells do not express the canonical EBV receptor CD21 [100], and this binding is sufficient to trigger the release of inflammatory mediators. Moreover, EBV induces neutrophils to produce IL-1α and IL-1β (Figure 1), but this is counteracted by a considerably stronger induction of IL-1R antagonist that neutralizes the proinflammatory activity of IL-1 [77]. IL-1Ra to IL-1 ratio of 10-100 is necessary to inhibit the IL-1 effects on target cells by 50% [101]. In response to EBV infection, the levels of secreted IL-1Ra in neutrophil supernatants are approximately 3600 and 610 times more than those of IL-1α and IL-1β, respectively [102], an indication of a predominant IL-1Ra response. By favouring the secretion of IL-1Ra, EBV may thereby shift the tightly regulated balance between IL-1 and IL-1Ra production. Expression of the chemotactic factors IL-8 and macrophage inflammatory protein (MIP)-1 was also detected in EBV-infected neutrophils [103]. The production of these cytokines by neutrophils could be involved in the recruitment of leukocytes in the lymphoid tissues and allow EBV a direct access to B cells. Two additional biological functions of neutrophils are known to be primed by EBV: the biosynthesis of leukotriene (LT) B4 and the production of reactive oxygen species [77]. LTβ4 exerts a wide array of immunoregulatory activities (Figure 1). Among others, it stimulates locomotion and chemotaxis of phagocytes, modulates lymphocyte as well as phagocyte functions and is also involved in the regulation of cytokines production [104]. In addition, LTβ4 enhances antitumor activities of NK cells and was recently reported to also exert antiviral activities [105]. Production and release of reactive superoxide anion, also known as respiratory burst activity, is another important function involved in destruction of viral particles. The fact that neutrophils become more responsive to the release of LTβ4 and O2− anion after interacting with EBV constitutes an alternative route for the immune defence to counteract viral invasion [77]. Therefore, the interaction of EBV with neutrophils has opposing influence on the initiation of immunity. Some of these effects such as the secretion of IL-1, IL-8, MIP-1α, LTβ4, and reactive superoxide anion, promote the development of EBV-specific immunity, while the upregulation of IL-1R and the induction of apoptosis in neutrophils inhibits anti-EBV immune responses [78].

Monocytes, Macrophages, and Dendritic Cells. In antiviral immune response, similarly to neutrophils, monocytes are rapidly recruited to sites of viral infection and were shown to adhere to flu-infected cells [106]. Monocytes are also known to play a key role in the initiation of specific immune responses. Moreover, they may contribute to host defence by mediating antibody-dependent cellular cytotoxicity (ADCC) via activation of NK cells. Episodes of monocytopenia were observed during the acute phase of IM [107]. In addition, patients with EBV-associated HL often show a deficiency in monocyte-mediated ADCC, suggesting that monocyte functions are affected during the course of EBV infection [77], as also demonstrated by the reduced phagocytic activity observed in EBV-infected monocytes [108]. This effect was probably caused by the impairment of protein kinase C (PKC) activity. EBV infection was found to prevent PMA-induced translocation of PKC and by altering the subcellular localization of the receptor for activated C kinase (RACK) 1 [109]. RACK1 is an essential anchoring protein that interacts and translocates with activated PKCs in response to a stimulus. Interactions of RACK1 with the EBV-encoded ZEBRA protein may inhibit PKC translocation and activation [77]. EBV infection inhibits also the functional ability of macrophages to respond to bacterial challenge [110] by reducing their phagocytic potential. The alteration of the phagocytic process is just an example of the EBV versatility exhibited to target the multiple facets of monocytes and macrophages antiviral activities.

Moreover, EBV directly binds the surface of approximately the 20% of monocytes, involving cellular receptors that are still not well characterized. Entry and translocation of EBV particles into the nucleus were visualized by electron microscopy and confirmed by the detection of EBV genome in isolated nuclei [108]. Interestingly, nuclear levels of viral genomic DNA were found to increase with time, suggesting that replication may actually occur in monocytes. Furthermore, although EBV propagation is mainly due to cell-cell contact that primarily involves B cells and epithelial cells, also monocytes and macrophages may participate in the transport of the virus and favour its propagation [111], especially within the oral epithelium, where EBV actively replicates and is released into the saliva [112]. The outcome of monocyte/EBV interaction is strongly influenced by the stage of differentiation of monocytes. Indeed, EBV infection inhibits the development of DCs from monocyte precursors [113] and the exposure to EBV induces apoptosis of a large proportion of monocytes cultured in the presence of GM-CSF and IL-4. Binding of EBV to monocytes through the viral membrane fusion complex may be sufficient to trigger events that will eventually lead to cell death. By inhibiting the differentiation of monocytes into mature DCs, EBV temporarily halts the onset of immune responses during primary infection, creating a time window for efficient viral replication. This permits the accumulation of a large pool of virus infected B-lymphocytes and allows their access to the memory B-cell compartment, interferes with the functions of DCs during the initiation of virus-specific immune response, and modifies the profile of secreted cytokines in order to create a favourable environment for viral propagation [77].
In this context, EBV has evolved over the millennia to modulate the cytokine network of the host in order to be not completely eliminated after primary infection and to promote its life-long persistence. Purified gp350/220, the major glycoprotein component of EBV envelope, induces secretion of IL-1, IL-6, and TNF-α by monocytes [77]. In this regard, during the course of primary infection, IL-1 and IL-6 are frequently detected in the serum and in tonsils of IM patients [114]. In addition, both IL-1 and IL-6 are actively secreted by EBV-immortalized B cells and have been shown to act as autocrine/paracrine growth factors for these cells (Figure 1). TNF-α can increase macrophage cytotoxicity, mediate natural cell cytotoxicity, and also participate in the regulation, maturation, activation, and lymphocytes proliferation. TNF-α was also reported to elicit antiviral activities against both RNA and DNA viruses (reviewed in [77]). Moreover, recombinant TNF-α was found to inhibit, in a dose-dependent manner, the proliferation and differentiation of both EBV-activated and transformed human B cells [115]. Therefore, it is not at all surprising that levels of TNF-α are detected in the serum of IM patients [114], an indication of the importance of this cytokine in the ongoing antiviral response. However, the entire virus inhibits the secretion of TNF-α by monocytes and macrophages, and, interestingly, neither peripheral blood mononuclear cells nor purified monocytes showed increased secretions of TNF-α in response to EBV [77]. EBV downregulated the cellular levels of TNF-α mRNA transcripts, suggesting that it may elicit its suppressive action at the transcriptional level. Furthermore, the virus inhibited the synthesis of the chemokine MIP-1α, thus reducing the recruitment of leukocytes. EBV was also found to induce the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) upon adsorption to the cell surface of monocytes [116]. Secretion of GM-CSF by monocytes was shown to synergize with EBV to enhance release of IL-8, MIP-1, and IL-1 by neutrophils (Figure 1), as well as the magnitude of EBV priming effect on superoxide and LTβ4 production. EBV differentially affected the production of leukotrienes and prostaglandins (PGs) in monocytes. The direct interaction of EBV gp350 with the cell surface is su

3.1.3. Epithelial Cells. Epithelial cells have an important role in the innate resistance to different pathogens and represent a preferential target of EBV infection, even if in vivo analysis revealed no evidence of EBV infection in salivary glands and only rare positivity in normal squamous epithelial cells at the tongue margin [121]. In this regard, kinetics studies performed in healthy individuals underlined the potential importance of epithelial cells in EBV replication and shedding, assuming that B cells sporadically release virus that infects epithelial cells, which in turn may contribute to amplify the amount of shed virus; thus the mouth is probably not a reservoir of the virus, but a conduit through which a continuous flow stream of virus passes in saliva [122]. However, since EBV can be detected in most undifferentiated NPC and in precancerous lesions, EBV infection has long been postulated to play an important role in NPC pathogenesis. It is worth mentioning in this respect that an in vitro model of EBV infection in premalignant nasopharyngeal epithelial cells was described by Tsang and colleagues [123]. The direct infection of epithelial cells requires the interaction between EBV glycoproteins gHgL and cellular αβ6 and αβ8 integrins [124]. In addition, an alternative process named “transfer infection” was proposed to explain the interplay between EBV and epithelial cells: the infection of memory B cells determines CD21-mediated capping of virus and activation of adhesion molecules, which in turn facilitates conjugate formation between B cells and epithelial cells and then the subsequent entry of EBV into epithelial cells [125]. EBV-positive cells, such as EBV-infected B-cells and EBV-carrying carcinoma cells, secrete exosomes enriched in LMP1 [126], which may interact with surrounding cells, in particular suppressing neighbouring T cells [127], thus contributing to immune modulation [128]. Moreover, in EBV-infected epithelial cells LMP2A and LMP2B accelerated the turnover of IFN receptors through processes requiring endosome acidification [129]. This function forms part of EBV strategy to limit antiviral responses. Interferons constitute a first line of defence against viral infection, serving to integrate innate and adaptive immune responses and limiting the replication and spread of viruses. IFNα and IFNβ (type I IFNs) block viral replication by inhibiting cellular protein synthesis, stimulating the expression of proinflammatory cytokines and orchestrating cellular immune responses. Similarly, IFN-γ (type II IFN) has a key function in “fine-tuning” the adaptive immune response. Whereas IFN-α and IFN-β share a common receptor, IFNAR, IFN-γ binds to IFNGR. The BZLF1 protein of EBV has been reported to downregulate transcription of the IFNGR during viral entry into lytic cycle, thereby protecting lytically infected cells from immune surveillance. Similarly, LMP2A and LMP2B attenuate IFN responses by influencing IFNAR and IFNGR stability (Figure 1), promoting their ubiquitination and the trafficking from endosomes to lysosomes. The ability of these viral proteins to modulate IFN signalling is another
example of a successful viral strategy for circumventing the innate immune response, an effect that is generally exploited in persistent virus infections but, in the context of oncogenic viruses such as EBV, may also contribute to tumor development [129].

3.1.4. Toll-Like Receptors. Innate immunity uses several pattern recognition receptors to sense pathogen-associated molecular patterns (PAMPs). The TLRs are the most studied pattern recognition receptors, and activation by pathogen components leads to robust immune response. TLR activation has probably multiple downstream effects during primary EBV infection, some of which may favor viral latency or reactivation and other may facilitate immune control. TLR9 was reported to recognize several PAMPs conserved on virions from different members of human herpesviruses. TLR9 is an important receptor for nucleic-acid-containing unmethylated CpG motifs present in both bacterial and viral DNA, whereas TLR7 senses single-stranded RNA [130]. A rapid detection of EBV particles during primary infection and the detection of secreted components or reactivated virus from EBV-infected cells are crucial for an efficient control of EBV infection. Intact viral particles are recognized by the membrane surface TLR2 (Figure 1) [131], likely through the interaction with gp350, the major envelope glycoprotein which mediates also EBV entry into B cells [132]. In addition, TLR2 is involved in the recognition of the unstructural protein dUTPase, which determines the activation of NF-κB via MyD88-dependent signalling cascade and induces expression of proinflammatory cytokines in macrophages [133]. Following viral entry into the cells, viral DNA is subsequently recognized by TLR9 (Figure 1). Such dual interactions, through TLR2 on cell membrane and by intracellular TLR9, lead to a rapid production of IL-8 to initiate an effective immune response. Production of MCP-1 and IL-10 by monocytes in response to EBV is mainly dependent on TLR2 rather than TLR9 [134]. Therefore, because monocytes express low levels of TLR9, it seems plausible that they have acquired the ability to use one TLR, in this case TLR2, to produce different cytokines to better respond to EBV before its entry into the cell. On the contrary, plasmacytoid DCs (pDCs) seem to recognize the virus primarily through TLR9 [134], which, in combination with TLR7 activation, could potentiate the production of type I IFNs via IRF7, promoting the activation of NK cells and IFN-γ producing CD3+ T cells [135]. Such recognition by a single cell type through multiple TLRs could then ensure an efficient innate response, but may also optimize the detection of the virus once it has escaped recognition by membrane TLR or intracellular TLR following entry into the cytosol. However, EBV has developed the ability to escape the innate immune response by downregulating TLR9 transcription [110]. Notably, the virus exerts this activity by using its major oncoprotein LMP1 via activation of NF-κB signalling. Primary B-cell infection by EBV resulted in an impairment of TLR9 pathway functionality, correlated with a decrease of TLR9 mRNA and protein levels in comparison with noninfected primary B cells [79]. In addition to TLR9, Fathallah et al. observed that EBV infection of primary B cells led to inhibition of TLR2 transcription and functionality [79]. Previous data showed that the major oncoproteins, E6 and E7, from the high-risk HPV type 16 inhibit the expression of TLR9. Thus, the ability to downregulate TLR9 expression is probably a shared property among DNA tumor viruses [136]. Interestingly, the low-risk HPV types, associated with benign cervical lesions, are unable to alter TLR9 expression, suggesting that TLR9 downregulation is an event exclusively associated with carcinogenic viruses [79].

The EBV noncoding RNAs, EBV-encoded RNA 1 (EBER1), and EBER2 are expected to form dsRNA-like structures [137]. EBER is the most abundant viral transcript in latently EBV-infected cells and binds to several cellular proteins including RNA-activated protein kinase (PKR), ribosomal protein 22 (L22), lupus erythematosis-associated antigen (La), and retinoic acid inducible gene 1 (RIG-I; reviewed in [138]). EBER exists in the sera of patients with active EBV infections and induces type I IFNs and inflammatory cytokines through TLR3-mediated signalling, which is a sensor of viral double-stranded RNA (dsRNA) [84]. This may account for the pathogenesis of active EBV infections that are characterized by cytokinemia. Furthermore, EBER1-treated DCs may induce primary immune responses, suggesting that during active infection, EBER1-mediated TLR3 stimulation is responsible for immune activation by EBV. TLR3 is predominantly expressed by DCs, but also by CD8+ T cells and NK cells, thus, circulating EBER1 could induce the activation of both DCs and T cells (Figure 1) [84]. These findings suggest that immunopathologic alterations that are caused by active EBV infections could be attributed to TLR3-mediated cytokinemia induced by EBER1, and that circulating EBER1 could be a potential target for therapeutic agents [84]. Moreover, EBERs may have several roles in EBV-driven tumorigenesis: EBER1 and EBER2 contribute to the clonal proliferation of EBV-negative BL cells in soft agar, promote tumorigenicity in SCID mice, upregulate the bcl-2 oncoprotein, induce resistance to apoptosis, and favour the maintenance of malignant phenotypes in BL cells. EBERs induce the expression of IL-10 in BL cells, insulin-like growth factor 1 (IGF-1) in gastric and NPC cells. In BL cells, EBERs prevent IFN-α-mediated apoptosis, while in epithelial cells these RNAs confer resistance to Fas-mediated apoptosis by blocking PKR activity. EBERs also play critical roles in the growth transformation of B lymphocytes [84, 138].

EBV is also able to induce the expression of cellular miRNA [131], in particular LMP1 signalling, through NF-κB and AP1, stimulates the expression of cellular miR-155, which in turn targets intermediates of innate immune signalling pathways [139]. In addition, during latency, the virus induces miR-146, involved in the attenuation of type I IFN production in macrophages [140], and miR-21 that negatively regulates TLR4 signaling [141].

Given the fact that B-cell activation and proliferation require the stimulation of TLR, it is possible that TLR ligand-bearing pathogens, such as bacteria colocalized at sites of EBV infection or replication (i.e., in tonsillitis during infectious mononucleosis), might favour EBV establishment and spread by increased proliferation of infected B cells. Similarly, bacterial or fungal coinfection could influence and
possibly aggravate PTLD by triggering TLRs on EBV infected B cells and thereby supporting their proliferation or modifying lytic EBV reactivation. Likewise, microbial infection may be a cofactor for EBV-associated BL, which mainly occurs in regions where malaria is endemic. EBV itself is a source of endogenous ligands of TLRs and other pattern recognition receptors (PRRs) and might be capable of triggering TLR9, mediated by hypomethylated CpG motifs in the viral DNA genome [142].

Understanding TLR implications during early and acute phases of EBV infection must therefore be investigated to further develop strategies to treat EBV infection, especially in immunosuppressed or autoimmune disease patients, in which EBV was suggested to exacerbate clinical symptoms [134].

3.2. Adaptive Immunity and EBV Infection. The recognition of antigens and their proper presentation and processing lead to the activation of specific adaptive immune responses that ultimately control the invading infectious agents. The central feature of immune memory is the ability of memory cells to mediate faster, stronger, and more effective responses to secondary pathogen challenges than naive cells. In this respect, humoral and cellular immunity play a critical role in controlling both the primary [143, 144] and persistent [143, 145] phases of virus infection. In particular, EBV stimulates strong humoral responses to some lytic cycle proteins: IgM and developing IgG responses to nucleocapsid and envelope proteins are in fact detectable in primary EBV infection. Moreover, IgG responses to some of the immediate early and early lytic cycle proteins and to the latent protein EBNA1 and 2 are also usually detectable, together with neutralizing antibodies directed against gp350. Therefore, humoral responses play an important role in controlling the spread of the virus in the late phases of infection, while cellular immunity is fundamental in controlling both the primary and persistent phases of EBV propagation. More precisely, cytotoxic T lymphocytes (CTL) are the major determinants in the control of acute EBV infection [146, 147] and are directed against both lytic and latent antigens [148]. More than 44% of the total CD8+ T cells in acute infection are specific for a single lytic EBV epitope, and most of these epitope-specific cells have an activated/memory phenotype [149]. Conversely, in the late stages of infection, the frequency of epitope-specific CD8+ T cells selectively increases against latent EBV proteins, confirming that CTLs are the most important cells for limiting infection in the convalescent phase of virus infection [149].

4. Immunotherapy Approaches against EBV-Associated Malignancies

The development of malignancies associated with EBV is largely favored by an underlying defect in EBV-specific CTL immunity and function. Therefore, much work has been focused in the last years on the reconstitution of CTL immunity to EBV in transplanted patients, who are at increased risk to develop PTLD as a consequence of iatrogenic immune suppression. Moreover, recent data indicate that other EBV-associated diseases such as NPC, HL, BL, and chronic active EBV infections (CAEBV) can potentially be treated with immunotherapeutic approaches.

4.1. EBV-Targeting Vaccines in Virus-Associated Malignancies. To date, the experience with human EBV vaccines is limited [150, 151] and, although potentially useful to prevent EBV associated malignancies, vaccines providing lifelong immunity against primary EBV infection might be unfeasible, considering that the type of immunity required to prevent repeated infection through mucosal surfaces is not clearly defined. Moreover, repeated infections with different EBV strains have been described [152], suggesting that the natural immune response to EBV is not sufficient to protect healthy EBV-positive individuals from recurrent infections. Nevertheless, it was clearly demonstrated that the risk of developing HL is 4-fold higher after resolution of IM, which is symptomatic of an abnormal primary EBV infection and then of a massive expansion of EBV-specific T cells [152]. Therefore, preventive vaccination to avoid uncontrolled virus replication and successive “scaring” of the immune system could decrease the incidence of EBV-associated malignancies. In particular, vaccine strategies for the immunotherapy of EBV-related tumors should seek to elicit or boost specific cellular immune response against EBV antigens expressed in these malignancies. Individuals likely to benefit from this approach are EBV-seronegative patients prior to solid organs transplant or patients with EBV-associated malignancies with a low tumor burden or in remission. However, vaccine strategies are unlikely to be the optimal method to enhance EBV-specific T-cell responses for patients who are immunocompromised, due to immunosuppressive therapies after transplantation or as a result of disease-related immune alterations such as in HL. In these cases, the adaptive immunotherapy with ex vivo activated EBV-specific CTL (EBV-CTLs) seems to be more promising, also because it allows genetic modifications of T cells able to enhance their function.

4.2. EBV-Specific Adoptive Immunotherapy (ACT) in PTLDs. EBV infection poses a significant problem in transplant patients who are iatrogenically immunosuppressed in order to prevent chronic organ rejection. Risk factors for the development of PTLD include EBV-seronegativity in the transplant recipient, the type of organ transplanted (highest in lung and heart and lowest in liver and kidney), and the level and type of immune suppression [27]. PTLD emerges as either of recipient or donor origin, depending on the type of transplant. For example, bone marrow transplant (BMT) patients develop PTLD of donor origin, as EBV-infected B cells derived from the donor marrow proliferate uncontrollably into lymphoma. Conversely, solid organ transplant patients develop PTLD of recipient origin, as EBV released from the transplanted organ infects the recipient’s B cells [28]. On these grounds, initial studies investigated the potential of EBV-specific CTLs to treat PTLD in BMT patients, as CTLs could be easily generated from EBV-seropositive, immunocompetent donors. Pioneering studies [153, 154] demonstrated that PTLD was resolved after

Clinical and Developmental Immunology
adoptive transfer of EBV-CTLs grown from donor peripheral blood mononuclear cells. The method developed to stimulate and expand large numbers of EBV-CTLs utilized donor’s autologous EBV-immortalized lymphoblastoid B-cell lines (LCLs), which were cocultured with donor PBMCs in the presence of interleukin-2 (IL-2). Similar to PTLD tumor cells, LCLs also have a latency III phenotype and can activate polyclonal EBV-specific CTLs with a broad reactivity to a range of EBNA- and LMPs-derived epitopes. The resulting EBV-CTLs used in these studies killed donor LCLs in vitro, did not compromise allograft function, and most importantly, eradicated tumors [154].

4.3. EBV-Specific ACT in NPC and HL. Clinical evidence accumulated so far indicates that ACT with EBV-CTLs is safe and well tolerated. Even if this approach results particularly effective in the case of most immunogenic tumors, as previously described in PTLDs [155], in Latency II EBV-associated malignancies, the more restricted pattern of viral latent antigen expression, together with local immune suppression and immune evasion of tumor cells, strongly limit the therapeutic potential of EBV-CTLs obtained by conventional protocols. In particular, the infusion of EBV-targeted autologous CTLs was shown to enhance specific immune responses and to induce objective clinical responses only in a proportion of NPC and HL cases [156, 157], probably due to the weak immunogenicity of LMPs [67, 158]. On these grounds, recombinant viruses encoding for EBNA1, LMP1, and LMP2 antigens have been used to improve protocols for the in vitro expansion of EBV-CTLs and in vivo data showed that they were also able to protect against LMP-positive tumor growth in mice [159–161]. Accordingly, interesting results were recently obtained by Bollard and colleagues on 10 selected HL patients, by the induction and in vivo persistence of LMP2-specific CTLs, using genetically modified APCs [162]. The authors showed that 9 of 10 patients treated in remission of a high-risk disease remained in remission, and 5 of 6 patients with active relapsed disease had a tumor response, which was complete in 4 and sustained for more than 9 months [162]. Furthermore, these EBV antigen-specific effector lines are being tested, with promising results, also in NPC patients [158, 163–165]. Unfortunately, although LMP2-specific CTLs could be expanded ex vivo after peptide-pulsed DC injection in NPC patients [156], these responses were usually weak or transient. Learning from these trials and as a result of a better understanding of the crucial role for CD4+ T cells in assisting CD8+ T-cell immunity, more recent stimulation protocols aim to incorporate both CD4+ and CD8+ T cell antigens [65, 158]. Indeed, in addition to CD4+ T-cell help for CD8+ T-cell responses, CD4+ T cells can also target and kill EBV-transformed B cells directly [166]. Finally, considering that NPC and HL malignant cells have functional antigen-processing machinery and express HLA and costimulatory molecules [72, 167], the demonstration that other viral latent proteins expressed by these neoplastic cells may serve as tumor-associated antigens could provide the rational background to improve the clinical efficacy of ACT protocols in this setting. Particularly promising in this respect is the demonstration that the oncogenic EBV-encoded BARF1 protein, expressed by most NPCs, is immunogenic and thus may be exploited as additional target of innovative ACT protocols [168]. Therefore, ACT with EBV-CTLs has proven to be an effective strategy in the post-transplant setting, being able to reconstitute EBV-specific immunity [23], to prevent the development of PTLD [28] and treat patients with established PTLD. For other EBV-associated malignancies, the use of EBV-CTL has proven less efficacious; however, the results obtained so far are sufficiently encouraging to justify continued active exploration of this approach. Novel approaches are being developed to enhance the potency of EBV-specific immunotherapy by targeting CTL to subdominant EBV proteins and by genetically modifying these effector cells to render them resistant against inhibitory cytokines or immunosuppressive therapies [169, 170]. Notably, such strategies could have relevant implications for the ACT of a broader spectrum of human cancers with defined tumor antigens. All these approaches open promising avenues to enhance or prime protective EBV-specific immune responses, which have been suppressed by the tumor cells itself or by their microenvironment, and whose absence might predispose for the development of EBV-associated malignancies.

5. Innate Immunity-Based Therapies for EBV-Driven Tumors

Traditional approaches to exploit innate immunity for cancer immunotherapy include the activation of endogenous effectors (mainly NK cells) with systemic administration of cytokines (IL-2, etc.) and the adoptive infusion of ex vivo expanded NK or lymphokine-activated killer (LAK) cells. The potent immunostimulatory effect of systemic IL-2 in advanced cancer patients has been originally demonstrated by the seminal work of Rosenberg and collaborators [171, 172]. Since then, several clinical trials based on IL-2 administration have been carried out in different cohorts of cancer patients, mainly including melanoma, renal cell carcinoma, neuroblastoma, breast cancer, and several hematologic malignancies [173–177]. Notably, low-dose IL-2 was successfully used for the treatment or prevention of lymphomas associated with human immunodeficiency virus (HIV) infection, which include a significant proportion of EBV+ cases [178]. In these lymphoma patients, IL-2 treatment results in increased absolute numbers of NK cells, with no significant change in T-cell subsets or plasma HIV RNA levels [179]. Clinical experience however indicate that IL-2 can cause systemic toxicities, a limitation that could be overcome by the use of IL-15, a less toxic cytokine that plays essential roles in NK cell development, homeostasis, and survival [180]. Moreover, availability of clinical-grade IL-15 also opens new avenues to improve the generation of NK cells for adoptive cancer immunotherapy [181]. It should be considered, however, that the ability of NK cells to recognize and kill tumor cells may be attenuated with progression of the disease through several mechanisms, including the upregulation of negative regulators of immune responses.
such as the ligand of Programmed Death-1 (PD-1) (PD-L1) [182, 183]. While the constitutive or inducible expression of PD-1 has been characterized in B, T, and dendritic cells, little is known regarding PD-1 expression on NK cells. Recent data indicate that the PD-1/PD-L1 signaling axis mediates NK cell activation and cytotoxicity against multiple myeloma. In particular, the use of a monoclonal antibody targeting the PD-1 molecule expressed by NK cells was shown to enhance NK cell cytotoxicity against tumor cells [184], providing the rationale to include these drugs in new therapeutic regimens for multiple myeloma. Several investigators have reported high levels of PD-1 expression on EBV-specific CD8⁺ T cells during acute or chronic infection [185, 186], but data on the expression of this inhibitory molecule on NK cells from patients with EBV-driven tumors are lacking.

Several lines of evidence indicate that innate immunity may usefully complement the antitumor immune responses induced by ACT. After total body irradiation, in fact, the damage of mucosal barriers results in the spreading of bacterial products, TLR agonists and proinflammatory cytokines that promote the activation of APC [187]. Moreover, it has been also demonstrated that TLR agonists may function as promising adjuvants for ACT protocols [188]. In a mouse melanoma model, TLR agonists were shown to enhance ACT in two functional phases: first, by favouring the interactions between activated host DCs and adoptively transferred CTLs; second, by enhancing the antitumor activity of T lymphocytes through IFNγ-dependent mechanisms [188]. This certainly constitutes a promising approach that deserves to be validated in humans. Besides working in combination with adoptively infused T cells, innate immunity effectors may be also used as a direct cell-based immunotherapy for human cancers, particularly those associated with oncogenic viruses. NK cells, in fact, can be an attractive alternative to ACT because they preferentially target MHC-class-I-deficient tumor cells. Moreover, NK cells can influence other immune cells by producing cytokines able to promote DC differentiation, antigen presentation, and CTL activity. Importantly, NK cells can eliminate immature, tolerizing DCs, allowing thus an improved presentation of tumor antigens to T cells. Pioneering studies by Velardi and coworkers demonstrated that alloreactive NK cells, if unrestrained by inhibitory signals from the recipient HLA ligands, are effective in protecting against disease relapse after hematopoietic stem cell transplantation [189]. Although available evidence indicates that alloreactive NK cells are effective in the setting of hematologic malignancies, this strategy remains to be extensively tested in patients with solid tumors, including EBV-associated carcinomas. Several methods are now available for ex vivo expansion of NK cells [190] and the critical issues related to the development of successful NK cell-based adoptive immunotherapy have been recently reviewed [191]. In the setting of EBV-driven tumors, exploitation of NK cells for therapeutic purposes seems particularly attractive, considering the pivotal role of these effectors in controlling EBV-infected cells. Moreover, IL-2-activated peripheral blood NK cells were shown to restrict EBV-induced B-cell transformation in vitro [86, 87] and activated NK cells acquire the ability to kill lytically EBV replicating B cells [192]. This latter effect was associated with downregulation of HLA class I molecules that bind to NK cell inhibitory receptors, whereas activating receptors remained upregulated [192]. In this respect EBV differs from human cytomegalovirus, which has evolved a complex and highly effective strategy for NK cell evasion. On these grounds, the current therapeutic approaches for EBV-related tumors based on the induction of EBV lytic replication would certainly benefit from a retained or even enhanced functionality of NK cells. It is worth considering in this respect that there is increasing interest in pharmacologic activation of lytic viral expression in EBV-driven malignancies [193]. Several drugs are able to trigger EBV lytic cycle, including gemcitabine, doxorubicin, various histone deacetylase inhibitors (trichostatin A, sodium butyrate, valproic acid, suberoylanilide hydroxamic acid), and bortezomib [193–195]. Particularly promising is the combination of EBV lytic cycle inducers with antiviral agents, as shown by the results of a phase I/II trial of arginine butyrate and gancyclovir in refractory EBV-associated lymphoid malignancies [196].

Cellular microRNAs (miRNAs) are emerging as new promising therapeutic targets for human cancers by virtue of their role in regulating numerous processes, also including immune responses [197]. In particular, recent advances have suggested new modalities to improve T-cell-based cancer immunotherapy by engineering distinct miRNAs. Targeting miR-17-92 is a promising approach considering that its downregulation in T cells from tumor-bearing mice and cancer patients is associated with a Th2 skewing and impaired antitumor responses [198]. Forced expression of miR-17-92 in T lymphocytes could therefore confer resistance to tumor-derived immunosuppressive factors, such as TGF-β and improve Th1 reactivity. Similarly, over-expression of miR-155 promotes Th1 differentiation of CD4⁺ T cells through the regulation of IFN-γRα chain [199]. Moreover, it has been shown that miR-181 regulates the strength and sensitivity of TCR-mediated T-cell activation by acting through modulation of multiple phosphatases [200]. It would be relevant to assess whether ectopic expression of miR-181 would lead to enhanced TCR signaling and a reduced T-cell activation threshold in T cells recognizing weak tumor-associated antigens. While the expression and importance of miRNAs in T and B lymphocytes have been established, little is known about the role of miRNAs in NK cells. The recent characterization of NK cell miRNA transcriptome by next-generation sequencing will provide a valuable framework to identify critical miRNAs that can be targeted to improve NK cell function in cancer patients [201]. Considering that NK cells also share an miRNA profile with effector and memory CD8⁺ T cells [202], the possibility to target miRNAs regulating pathways common to innate and adaptive immunity appears particularly attractive. miRNAs expressed by EBV-infected tumor cells may be also relevant for therapeutic purposes. In fact, cellular miRNAs 200b and 429 are key regulators of the switch between latent and lytic EBV infection, thus constituting attractive targets for the development of new lytic induction therapeutics [203].
6. Concluding Remarks

Innate and adaptive immunity are both crucial for an effective control of an oncogetic virus such as EBV. The success of adoptive T-cell therapy for EBV-driven PTLDs is stimulating the development of new immunotherapeutic strategies for EBV-associated tumors. Considering that adaptive immunity has coevolved with innate immunity to warrant protection from infections, innovative immunotherapeutic approaches should take into account both compartments to be more clinically effective. Evidence accumulated so far indicates that innate immunity effectors, particularly NK cells, can be exploited with therapeutic purposes and new targets have been recently identified. Nevertheless, only few clinical studies are investigating the possible efficacy of treatments exploiting both innate and adaptive antitumor immunity. EBV-driven tumors constitute a particularly suitable setting to address this clinically relevant issue.

Authors’ Contribution

D. Martorelli and E. Muraro equally contributed to the work.

Acknowledgments

The study was supported in part by Grants from the European Community (FP6 VITAL, Contract no. 037874), the Italian Ministry of Health program “Alleanza Contro il Cancro” (ACC-4), the Associazione Italiana per la Ricerca sul Cancro (Contract 10301 to R. Dolcetti), and the Fondazione per la Vita.

References

[1] P. M. Arlen, “Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches,” Oncology, vol. 25, no. 3, pp. 261–262, 2011.
[2] K. Palucka, H. Ueno, and J. Banchereau, “Recent developments in cancer vaccines,” Journal of Immunology, vol. 186, no. 3, pp. 1325–1331, 2011.
[3] R. Madan and J. Gulley, “The current and emerging role of immunotherapy in prostate cancer,” Clinical Genitourinary Cancer, vol. 8, no. 1, pp. 10–16, 2010.
[4] S. Cecco, E. Muraro, E. Giacomin et al., “Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives,” Current Cancer Drug Targets, vol. 11, no. 1, pp. 85–102, 2011.
[5] V. Vonka, “Immunotherapy of chronic myeloid leukemia: present state and future prospects,” Immunotherapy, vol. 2, no. 2, pp. 227–241, 2010.
[6] M. J. Beser, L. Hershkovitz, J. Schachter, and A. J. Treves, “Focus on adoptive T cell transfer trials in melanoma,” Clinical and Developmental Immunology, vol. 2010, pp. 260–267, 2010.
[7] S. C. Goldstein and D. L. Porter, “Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies,” Expert Review of Hematology, vol. 3, no. 3, pp. 301–314, 2010.
[8] K. K. Jain, “Personalized cancer vaccines,” Expert Opinion on Biological Therapy, vol. 10, no. 12, pp. 1637–1647, 2010.
[9] F. Chen, J. Z. Zou, L. Di Renzo et al., “A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1,” Journal of Virology, vol. 69, no. 6, pp. 3752–3758, 1995.
[10] G. J. Babcock, D. Hochberg, and D. A. Thorley-Lawson, “The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell,” Immunity, vol. 13, no. 4, pp. 497–506, 2000.
[11] R. Dolcetti and M. G. Masucci, “Epstein-Barr virus: induction and control of cell transformation,” Journal of Cellular Physiology, vol. 196, no. 2, pp. 207–218, 2003.
[12] M. R. Lerner, N. C. Andrews, G. Miller, and J. A. Steitz, “Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 2, pp. 805–809, 1981.
[13] C. H. Lecler, P. Dunoyer, K. Arar et al., “A cellular microRNA mediates antiviral defense in human cells,” Science, vol. 308, no. 5721, pp. 557–560, 2005.
[14] S. Pfeffer, M. Zavolan, F. A. Grasser et al., “Identification of virus-encoded microRNAs,” Science, vol. 304, no. 5671, pp. 734–736, 2004.
[15] C. S. Sullivan, A. T. Grundhoff, S. Teveithia, J. M. Pipas, and D. Ganem, “SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells,” Nature, vol. 435, no. 7042, pp. 682–686, 2005.
[16] D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.
[17] V. Ambros, “The functions of animal microRNAs,” Nature, vol. 431, no. 7006, pp. 350–355, 2004.
[18] J. S. Mattick and I. V. Makunin, “Small regulatory RNAs in mammals,” Human Molecular Genetics, vol. 14, no. 1, pp. R121–R132, 2005.
[19] P. Xu, M. Guo, and B. A. Hay, “MicroRNAs and the regulation of cell death,” Trends in Genetics, vol. 20, no. 12, pp. 617–624, 2004.
[20] A. Esquela-Kersch and F. J. Slack, “Oncomirs—microRNAs with a role in cancer,” Nature Reviews Cancer, vol. 6, no. 4, pp. 259–269, 2006.
[21] J. Kluiver, S. Poppema, D. De Jong et al., “BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas,” Journal of Pathology, vol. 207, no. 2, pp. 243–249, 2005.
[22] S. A. Connolly, J. O. Jackson, T. S. Jardetzky, and R. Longenecker, “Fusing structure and function: a structural view of the herpesvirus entry machinery,” Nature Reviews Microbiology, vol. 9, no. 5, pp. 369–381, 2011.
[23] A. B. Rickinson and E. D. Kieff, “Epstein-Barr virus,” in Field Virology, pp. 2655–706, Lippincott Williams & Wilkins, Philadelphia, PA, USA, 5th edition, 2007.
[24] K. Gatter and G. Desol, “AIDS-related lymphomas: from pathogenesis to pathology,” The British Journal of Haematology, vol. 130, no. 5, pp. 662–670, 2005.
[25] A. A. Brink, D. F. Dukers, A. J. C. van den Brule et al., “Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas,” Journal of Clinical Pathology, vol. 50, no. 11, pp. 911–918, 1997.
[27] P. J. Pickhardt and M. J. Siegel, "Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients," Radiology, vol. 213, no. 1, pp. 73–78, 1999.

[28] Q. Tao, L. S. Young, C. B. J. Woodman, and P. G. Murray, "Epstein-Barr virus (EBV) and its associated human cancers—genetics, epigenetics, pathobiology and novel therapeutics," Frontiers in Bioscience, vol. 11, no. 2, pp. 2672–2713, 2006.

[29] S. Keay, D. Oldach, A. Wiland et al., "Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients," Clinical Infectious Diseases, vol. 26, no. 3, pp. 596–600, 1998.

[30] R. Purighalla, R. Shapiro, M. L. Jordan et al., "Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder," Clinical Transplantation, vol. 11, no. 6, pp. 574–576, 1997.

[31] S. A. Birkenland, H. K. Andersen, and S. J. Hamilton-Dutoit, "Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol," Transplantation, vol. 67, no. 9, pp. 1209–1214, 1999.

[32] M. Hummel, I. Anagnostopoulos, P. Korbjuhn, and H. Stein, "Epstein-Barr virus in B-cell non-Hodgkin’s lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types," Journal of Pathology, vol. 175, no. 3, pp. 263–271, 1995.

[33] B.E. Griffin and R. Rochford, Endemic Burkitt’s Lymphoma, Caister Academic Press, Norfolk, UK, 2005.

[34] J. B. Wilson, F. Wang, J. Kutok et al., "Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice," EMBO Journal, vol. 15, no. 12, pp. 3117–3126, 1996.

[35] N. Kitagawa, M. Goto, K. Kurozumi et al., "Epstein-Barr virus-encoded poly(A)- RNA supports Burkitt’s lymphoma growth through interleukin-10 induction," EMBO Journal, vol. 19, no. 24, pp. 6742–6750, 2000.

[36] R. Kuppers and R. Dalla-Favera, "Mechanisms of chromosomal translocations in B cell lymphomas," Oncogene, vol. 20, no. 40, pp. 5580–5594, 2001.

[37] C. M. Borza and L. M. Hutt-Fletcher, "Alternate replication of the p53 tumour surveillance network by tumour-derived MYC mutants," Nature, vol. 436, no. 7052, pp. 807–811, 2005.

[38] A. Egle, A. W. Harris, P. Bouillet, and S. Cory, "Bim is a suppressor of Myc-induced mouse B cell leukemia," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 16, pp. 6614–6619, 2004.

[39] K. N. Heller, F. Arrey, P. Steinherz et al., "Patients with Epstein-Barr virus-positive lymphomas have decreased CD4 + T-cell responses to the viral nuclear antigen 1," International Journal of Cancer, vol. 123, no. 12, pp. 2824–2831, 2008.

[40] J. L. Kutok and F. Wang, "Spectrum of Epstein-Barr virus-associated diseases," Annual Review of Pathology, vol. 1, pp. 375–404, 2006.

[41] H. Herbst, H. D. Foss, J. Samol et al., "Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin’s disease," Blood, vol. 87, no. 7, pp. 2918–2929, 1996.

[42] S. M. Hsu, J. Lin, S. S. Xie, P. L. Hsu, and S. Rich, "Abundant expression of transforming growth factor-β1 and -β2 by Hodgkin’s Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin’s disease," Human Pathology, vol. 24, no. 3, pp. 249–255, 1993.

[43] N. A. Marshall, L. E. Christie, L. R. Munro et al., "Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma," Blood, vol. 103, no. 5, pp. 1755–1762, 2004.

[44] J. B. Wilson, F. Wang, J. Kutok et al., "Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice," EMBO Journal, vol. 15, no. 12, pp. 3117–3126, 1996.
Clinical and Developmental Immunology

[58] I. Anagnostopoulos, M. Hummel, C. Kreschel, and H. Stein, "Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus," *Blood*, vol. 85, no. 3, pp. 744–750, 1995.

[59] G. Niedobitek, A. Agathangelou, N. Steven, and L. S. Young, "Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells," *Journal of Clinical Pathology—Molecular Pathology*, vol. 53, no. 1, pp. 37–42, 2000.

[60] S. D. Hudnall, Y. Ge, L. Wei, N. P. Yang, H. Q. Wang, and T. Chen, "Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils," *Modern Pathology*, vol. 18, no. 4, pp. 519–527, 2005.

[61] D. K. Paramita, C. Fatmawati, H. Juwana et al., "Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls," *Journal of Medical Virology*, vol. 83, no. 4, pp. 665–678, 2011.

[62] M. Y. Liu, Y. T. Huang, T. S. Sheen, J. Y. Chen, and C. H. Tsai, "Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma," *Journal of Medical Virology*, vol. 73, no. 4, pp. 574–582, 2004.

[63] G. Henle and W. Henle, "Epstein-Barr virus specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma," *International Journal of Cancer*, vol. 17, no. 1, pp. 1–7, 1976.

[64] A. D. Hislop, N. E. Annels, N. H. Gudgeon, A. M. Leese, and A. B. Rickinson, "Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection," *Journal of Experimental Medicine*, vol. 195, no. 7, pp. 893–905, 2002.

[65] X. Lin, N. H. Gudgeon, E. P. Hui et al., "CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients," *Cancer Immunology, Immunotherapy*, vol. 57, no. 7, pp. 963–975, 2008.

[66] J. Li, X. H. Zeng, H. Y. Mo et al., "Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumour immunotherapy," *PLoS One*, vol. 2, no. 11, Article ID e1122, 2007.

[67] P. Comoli, P. Pedrazzoli, R. Maccario et al., "Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes," *Journal of Clinical Oncology*, vol. 23, no. 35, pp. 8942–8949, 2005.

[68] K. M. Lau, S. H. Cheng, K. W. Lo et al., "Increase in circulating Foxp3 + CD4 + CD25(high) regulatory T cells in nasopharyngeal carcinoma patients," *The British Journal of Cancer*, vol. 96, no. 4, pp. 617–622, 2007.

[69] J. Kilibi, T. Niki, A. Riedel et al., "Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells," *Blood*, vol. 113, no. 8, pp. 1957–1966, 2009.

[70] M. Yao, K. Oshihama, J. Suzukiya, T. Kume, T. O. Shiroshita, and M. Kikuchi, "Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus-associated nasopharyngeal carcinoma," *International Journal of Cancer*, vol. 72, no. 3, pp. 398–402, 1997.

[71] A. Beck, D. Pzolt, G. G. Grabenbauer et al., "Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin's disease," *Journal of Pathology*, vol. 194, no. 2, pp. 145–151, 2001.

[72] R. Khanna, P. Busson, S. R. Burrows et al., "Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells," *Cancer Research*, vol. 58, no. 2, pp. 310–314, 1998.

[73] T. Ogino, S. Moriai, Y. Ishida et al., "Association of immune escape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma," *International Journal of Cancer*, vol. 120, no. 11, pp. 2401–2410, 2007.

[74] S. M. Krams and O. M. Martinez, "Epstein-Barr virus, rapamycin, and host immune responses," *Current Opinion in Organ Transplantation*, vol. 13, no. 6, pp. 563–568, 2008.

[75] F. Pietersma, E. Piriou, and D. van Baren, "Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients," *Leukemia and Lymphoma*, vol. 49, no. 6, pp. 1028–1041, 2008.

[76] D. Ikawiri and K. Takada, "Role of EBERs in the pathogenesis of EBV infection," *Advances in Cancer Research*, vol. 107, pp. 119–136, 2010.

[77] M. Savard and J. Gosselin, "Epstein-Barr virus immunosuppression of innate immunity mediated by phagocytes," *Virus Research*, vol. 119, no. 2, pp. 134–145, 2006.

[78] V. Levitsky and M. G. Masucci, "Manipulation of immune responses by Epstein-Barr virus," *Virus Research*, vol. 88, no. 1–2, pp. 71–86, 2002.

[79] I. Fathallah, P. Parroche, H. Gruffat et al., "EBV latent membrane protein 1 is a negative regulator of TLR9," *Journal of Immunology*, vol. 185, no. 11, pp. 6439–6447, 2010.

[80] G. Trinchieri, "Biology of natural killer cells," *Advances in Immunology*, vol. 47, pp. 187–376, 1989.

[81] M. A. Degli-Esposti and M. J. Smyth, "Close encounters of different kinds: dendritic cells and NK cells take centre stage," *Nature Reviews Immunology*, vol. 5, no. 2, pp. 112–124, 2005.

[82] M. A. Cooper, T. A. Fehniger, and M. A. Caligiuri, "The biology of human natural killer-cell subsets," *Trends in Immunology*, vol. 22, no. 11, pp. 633–640, 2001.

[83] T. A. Fehniger, M. A. Cooper, G. J. Nuovo et al., "CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity," *Blood*, vol. 101, no. 8, pp. 3052–3057, 2003.

[84] D. Ikawiri, L. Zhou, M. Samanta et al., "Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3," *Journal of Experimental Medicine*, vol. 206, no. 10, pp. 2091–2099, 2009.

[85] G. Ferlazzo, M. Pack, D. Thomas et al., "Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 47, pp. 16606–16611, 2004.

[86] T. Strowig, F. Brilot, F. Arrey et al., "Tonsilar NK cells restrict B cell transformation by the epstein-barr virus via IFN-γ," *PLoS Pathogens*, vol. 4, no. 2, p. e27, 2008.

[87] L. Benoit, X. Wang, H. F. Pabst, J. Dutz, and R. Tan, "Defective NK cell activation in X-linked lymphoproliferative disease," *Journal of Immunology*, vol. 165, no. 7, pp. 3549–3553, 2000.

[88] O. Devergne, A. Coulomb-L’Hermin´e, F. Capel, M. Moussa, and F. Capron, "Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts," *The American Journal of Pathology*, vol. 159, no. 5, pp. 1763–1776, 2001.
[89] F. Larousserie, E. Bardel, S. Pflanz et al., “Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas; heterogeneous expression of EBI3 subunit by tumoral cells,” The American Journal of Pathology, vol. 166, no. 4, pp. 1217–1228, 2005.

[90] F. Locatelli, D. Pende, R. Maccario, M. C. Mingari, A. Moretta, and L. Moretta, “Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference,” Clinical Immunology, vol. 135, no. 2, pp. 171–178, 2009.

[91] P. Comolli, S. Basso, M. Zecca et al., “Preemptive therapy of EBV-related lymphopoiferative disease after pediatric haploidentical stem cell transplantation,” The American Journal of Transplantation, vol. 7, no. 6, pp. 1648–1655, 2007.

[92] M. A. Cassatella, S. Gasperini, and M. P. Russo, “Cytokine and myeloperoxidase and neutrophils,” Blood, vol. 86, no. 7, pp. 2789–2798, 1995.

[93] S. Calattini, I. Sereti, P. Scheinberg, H. Kimore, R. W. Childs, and J. I. Cohen, “Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using immuno-FISH,” Blood, vol. 116, no. 22, pp. 4546–4559, 2010.

[94] H. Vallhov, C. Gutzeit, S. M. Johansson et al., “Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro,” Journal of Immunology, vol. 186, no. 1, pp. 73–82, 2011.

[95] D. M. Pegtel, K. Cosmopoulos, D. A. Thorley-Lawson et al., “Functional delivery of viral miRNAs via exosomes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 14, pp. 6328–6333, 2010.

[96] K. F. Eriksson, L. Holmberg, and C. G. Bergstran, “Infectious mononucleosis and agranulocytosis,” Scandinavian Journal of Infectious Diseases, vol. 11, no. 4, pp. 307–309, 1979.

[97] W. P. Hammond, J. M. Harlan, and S. E. Steinberg, “Severe neutropenia in infectious mononucleosis,” Western Journal of Medicine, vol. 131, no. 2, pp. 92–97, 1979.

[98] Y. Kagoya, A. Hangaishi, T. Takahashi, Y. Imai, and M. Kurokawa, “High-dose dexamethasone therapy for severe thrombocytopenia and neutropenia induced by EBV infectious mononucleosis,” International Journal of Hematology, vol. 91, no. 2, pp. 326–327, 2010.

[99] B. Larochelle, L. Flamand, P. Gourde, D. Beauchamp, and J. Gosselin, “Epstein-Barr virus infects and induces apoptosis in human neutrophils,” Blood, vol. 92, no. 1, pp. 291–299, 1998.

[100] A. D. Beaulieu, R. Paquin, and J. Gosselin, “Epstein-Barr virus modulates de novo protein synthesis in human neutrophils,” Blood, vol. 86, no. 7, pp. 2789–2798, 1995.

[101] W. P. Arena, M. Malyak, C. J. Guthridge, and C. Gabay, “Interleukin-1 receptor antagonist: role in biology,” Annual Review of Immunology, vol. 16, pp. 27–55, 1998.

[102] C. J. Roberge, P. E. Poubelle, A. D. Beaulieu, D. Heitz, and J. Gosselin, “The IL-1Ra and IL-1 receptor antagonist (IL-1Ra) response of human neutrophils to EBV stimulation: preponderance of IL-1Ra detection,” Journal of Immunology, vol. 156, no. 12, pp. 4884–4891, 1996.

[103] S. R. McColl, C. J. Roberge, B. Larochelle, and J. Gosselin, “EBV induces the production and release of IL-8 and macrophage inflammatory protein-1 alpha in human neutrophils,” Journal of Immunology, vol. 159, no. 12, pp. 6164–6168, 1997.

[104] M. Peters-Golden, C. Canetti, P. Mancuso, and M. J. Coffey, “Leukotrienes: underappreciated mediators of innate immune responses,” Journal of Immunology, vol. 174, no. 2, pp. 589–594, 2005.

[105] J. Gosselin, P. Borget, and L. Flamand, “Leukotriene B4 protects latently infected mice against murine cytomegalovirus reactivation following allogeneic transplantation,” Journal of Immunology, vol. 174, no. 3, pp. 1587–1593, 2005.

[106] D. R. Ratcliffe, S. L. Nolin, and E. B. Cramer, “Neutrophil interaction with influenza-infected epithelial cells,” Blood, vol. 72, no. 1, pp. 142–149, 1988.

[107] E. Svedmyr, I. Ernberg, and J. Seeley, “Viroid logic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis,” Clinical Immunology and Immunopathology, vol. 30, no. 3, pp. 437–450, 1984.

[108] M. Savard, C. Bélanger, M. Tardif, P. Gourde, L. Flamand, and J. Gosselin, “Infection of primary human monocytes by Epstein-Barr virus,” Journal of Virology, vol. 74, no. 6, pp. 2612–2619, 2000.

[109] M. Tardif, M. Savard, L. Flamand, and J. Gosselin, “Impaired protein kinase C activation/translocation in Epstein-Barr virus-infected monocytes,” Journal of Biological Chemistry, vol. 277, no. 27, pp. 24148–24154, 2002.

[110] Y.-L. Lin and M. Li, “Human cytomegalovirus and Epstein-Barr virus inhibit oral bacteria-induced macrophage activation and phagocytosis,” Oral Microbiology and Immunology, vol. 24, no. 3, pp. 243–248, 2009.

[111] P. Speck, K. M. Haan, and R. Longnecker, “Epstein-Barr virus entry into cells,” Virology, vol. 277, no. 1, pp. 1–5, 2000.

[112] S. Tugizov, R. Herrera, F. Velupillai, J. Greenspan, D. Greenspan, and J. M. Palefsky, “Epstein-Barr virus (EBV)-infected monocytes facilitate dissemination of EBV within the oral mucosal epithelium,” Journal of Virology, vol. 81, no. 11, pp. 5484–5496, 2007.

[113] L. Li, D. Liu, L. Hutt-Fletcher, A. Morgan, M. G. Musacci, and V. Levitsky, “Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage colony-stimulating factor and interleukin-4,” Blood, vol. 99, no. 10, pp. 3725–3734, 2002.

[114] V. Wright-Browne, A. M. Schnee, M. A. Jenkins et al., “Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence,” Leukemia and Lymphoma, vol. 30, no. 5-6, pp. 583–589, 1998.

[115] O. Janssen and D. Kabelitz, “Tumor necrosis factor selectively inhibits activation of human B cells by Epstein-Barr virus,” Journal of Immunology, vol. 140, no. 1, pp. 125–130, 1988.

[116] C. J. Roberge, B. Larochelle, M. Rola-Pleszczynski, and J. Gosselin, “Epstein-Barr virus induces GM-CSF synthesis by monocytes: effect on EBV-induced IL-1 and IL-1 receptor antagonist production in neutrophils,” Virology, vol. 238, no. 2, pp. 344–352, 1997.

[117] J. Gosselin and P. Borget, “Epstein-Barr virus modulates 5-lipoxygenase product synthesis in human peripheral blood mononuclear cells,” Blood, vol. 89, no. 6, pp. 2122–2130, 1997.

[118] J. Marcinkiewicz and B. M. Chain, “Differential cytokine regulation by eicosanoids in T cells primed by contact sensitization with TNP,” Cellular Immunology, vol. 149, no. 2, pp. 303–314, 1993.

[119] E. R. Fedyk, D. M. Brown, and R. P. Phipps, “PGE2 regulation of B lymphocytes and T helper 1 and T helper 2 cells:
induction of inflammatory versus allergic responses,” *Advances in Experimental Medicine and Biology*, vol. 407, pp. 237–242, 1996.

[120] J. I. Cohen and K. Lekstrom, “Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells,” *Journal of Virology*, vol. 73, no. 9, pp. 7627–7632, 1999.

[121] P. Frangou, M. Buettner, and G. Niedobitek, “Epstein-Barr virus (EBV) infection in epithelial cells in vivo: rare detection of EBV replication in tongue mucosa but not in salivary glands,” *Journal of Infectious Diseases*, vol. 191, no. 2, pp. 238–242, 2005.

[122] V. Hadinoto, M. Shapiro, C. C. Sun, and D. A. Thorley-Lawson, “The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output,” *PLoS Pathogens*, vol. 5, no. 7, Article ID e1000496, 2009.

[123] C. M. Tsang, G. Zhang, E. Seto et al., “Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of infection and phenotypic characterization,” *International Journal of Cancer*, vol. 127, no. 7, pp. 1570–1583, 2010.

[124] L. S. Chesnokova, S. L. Nishimura, and L. M. Hutt-Fletcher, “Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta5 or alphavbeta8,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 48, pp. 20464–20469, 2009.

[125] C. Shannon-Lowe and M. Rowe, “Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection,” *PLoS Pathogens*, vol. 7, no. 5, Article ID e1001338, 2011.

[126] C. Keryer-Bibens, C. Pioche-Durieu, C. Villemant et al., “Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral Latent Membrane Protein 1 and the immunomodulatory protein galectin 9,” *BMC Cancer*, vol. 6, p. 283, 2006.

[127] J. Flanagan, J. Middeldorp, and T. Sculley, “Localization of the Epstein-Barr virus protein LMP 1 to exosomes,” *Journal of General Virology*, vol. 84, no. 7, pp. 1871–1879, 2003.

[128] J. M. Middeldorp and D. M. Pegtel, “Multiple roles of LMP1 in Epstein-Barr virus induced immune escape,” *Seminars in Cancer Biology*, vol. 18, no. 6, pp. 388–396, 2008.

[129] K. M. Shah, S. E. Stewart, W. Wei et al., “The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation,” *Oncogene*, vol. 28, no. 44, pp. 3903–3914, 2009.

[130] S. Bauer, T. Muller, and S. Hamm, “Pattern recognition by Toll-like receptors,” *Advances in Experimental Medicine and Biology*, vol. 653, pp. 13–34, 2009.

[131] S. Ning, “Innate immune modulation in EBV infection,” *Herpesvirusidae*, vol. 2, no. 1, p. 1, 2011.

[132] E. Gaudreault, S. Fiola, M. Olivier, and J. Gosselin, “Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2,” *Journal of Virology*, vol. 81, no. 15, pp. 8016–8024, 2007.

[133] M. E. Ariza, R. Glaser, P. T. P. Kaumaya, C. Jones, and M. V. Williams, “The EBV-encoded dUTPase activates NF-κB through the TLR2 and MyD88-dependent signaling pathway,” *Journal of Immunology*, vol. 182, no. 2, pp. 851–859, 2009.

[134] S. Fiola, D. Gosselin, K. Takada, and J. Gosselin, “TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells,” *Journal of Immunology*, vol. 185, no. 6, pp. 3620–3631, 2010.

[135] H. L. Wai, S. Kireta, G. R. Russ, and P. T. H. Coates, “Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice,” *Blood*, vol. 109, no. 3, pp. 1043–1050, 2007.

[136] U. A. Hasan, E. Bates, F. Takeshita et al., “TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16,” *Journal of Immunology*, vol. 178, no. 5, pp. 3186–3197, 2007.

[137] M. D. Rosa, E. Gottlieb, M. R. Lerner, and J. A. Steitz, “Striking similarities are exhibited by two small Epstein-Barr virus-encoded ribonucleic acids and the adenovirus-associated ribonucleic acids VAI and VAl,” *Molecular and Cellular Biology*, vol. 1, no. 9, pp. 785–796, 1981.

[138] M. Samanta and K. Takada, “Modulation of innate immunity system by Epstein-Barr virus-encoded non-coding RNA and oncogenesis,” *Cancer Science*, vol. 101, no. 1, pp. 29–35, 2010.

[139] G. Gatto, A. Rossi, D. Rossi, S. Kroening, S. Bonatti, and M. Mallardo, “Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-κB pathway,” *Nucleic Acids Research*, vol. 36, no. 20, pp. 6608–6619, 2008.

[140] J. Hou, P. Wang, L. Lin et al., “MicroRNA-146a feedback inhibits RIG-I-dependent type I interferon production in macrophages by targeting TRAF6, IRAK1, and IRAK2,” *Journal of Immunology*, vol. 183, no. 3, pp. 2150–2158, 2009.

[141] F. J. Sheedy, E. Plasson-Mcdermott, E. J. Hennessy et al., “Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21,” *Nature Immunology*, vol. 11, no. 2, pp. 141–147, 2010.

[142] S. Iskra, M. Kalla, H. J. Delecluse, W. Hammerschmidt, and A. Moosmann, “Toll-like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-Barr virus,” *Journal of Virology*, vol. 84, no. 7, pp. 3612–3623, 2010.

[143] H. H. Niller, H. Wolf, and J. Minaarowits, “Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases,” *Autoimmunity*, vol. 41, no. 4, pp. 298–328, 2008.

[144] A. D. Hislop, G. S. Taylor, D. Sauce, and A. B. Rickinson, “Cellular responses to viral infection in humans: lessons from Epstein-Barr virus,” *Annual Review of Immunology*, vol. 25, pp. 587–617, 2007.

[145] S. Pai and R. Khanna, “Role of LMP1 in immune control of EBV infection,” *Seminars in Cancer Biology*, vol. 11, no. 6, pp. 455–460, 2001.

[146] A. B. Rickinson and D. J. Moss, “Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection,” *Annual Review of Immunology*, vol. 15, pp. 405–431, 1997.

[147] Y. Hoshino, T. Morishima, H. Kimura, K. Nishikawa, T. Tsurumi, and K. Kuzushima, “Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection,” *Journal of Immunology*, vol. 163, no. 10, pp. 5735–5740, 1999.

[148] N. M. Steven, N. E. Annels, A. Kumar, A. M. Leese, M. G. Kurilla, and A. B. Rickinson, “Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response,” *Journal of Experimental Medicine*, vol. 185, no. 9, pp. 1605–1617, 1997.

[149] M. F. Callan, L. Tan, N. Annels et al., “Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo,” *Journal of Experimental Medicine*, vol. 187, no. 9, pp. 1395–1402, 1998.
[150] S. Y. Gu, T. M. Huang, L. Ruan et al., “First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen,” *Development in Biological Standardization*, vol. 84, pp. 171–177, 1995.

[151] R. Khanna, D. J. Moss, and S. R. Burrows, “Vaccine strategies against Epstein–Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation,” *Immunological Reviews*, vol. 170, pp. 49–64, 1999.

[152] H. Hjalgrim, J. Askling, K. Rostgaard et al., “Characteristics of Hodgkin’s lymphoma after infectious mononucleosis,” *The New England Journal of Medicine*, vol. 349, no. 14, pp. 1324–1332, 2003.

[153] H. E. Heslop, M. K. Brenner, C. Rooney et al., “Administration of neomycin resistance gene marked EBV specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts,” *Human Gene Therapy*, vol. 5, no. 3, pp. 381–397, 1994.

[154] C. M. Rooney, C. A. Smith, C. Y. C. Ng et al., “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” *The Lancet*, vol. 345, no. 8941, pp. 9–13, 1995.

[155] A. M. Leen and H. E. Heslop, “Cytotoxic T lymphocytes as immune-therapy in haematological practice,” *The British Journal of Haematology*, vol. 143, no. 2, pp. 169–179, 2008.

[156] C. L. Liu, W. F. Lo, T. H. Lee et al., “Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma,” *Cancer Research*, vol. 62, no. 23, pp. 6952–6958, 2002.

[157] C. M. Bollard, L. Aguilar, K. C. Straathof et al., “Cytotoxic T lymphocyte therapy for Epstein-barr virus+ Hodgkin’s disease,” *Journal of Experimental Medicine*, vol. 200, no. 12, pp. 1623–1633, 2004.

[158] J. Li, Q. Chen, H. Mo, Y. Zhang, Z. Huang, and Y. Zeng, “Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy,” *International Journal of Biological Sciences*, vol. 7, no. 5, pp. 607–617, 2011.

[159] C. Smith, L. Cooper, M. Burgess et al., “Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope,” *Journal of Immunology*, vol. 177, no. 7, pp. 4897–4906, 2006.

[160] J. Duraliaswamy, M. Bharadwaj, J. Tellam et al., “Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine,” *Cancer Research*, vol. 64, no. 4, pp. 1483–1489, 2004.

[161] S. Landmeier, B. Altwater, S. Fischer et al., “Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer,” *Journal of Immunotherapy*, vol. 32, no. 3, pp. 310–321, 2009.

[162] C. M. Bollard, S. Gottschalk, A. M. Leen et al., “Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer,” *Blood*, vol. 110, no. 8, pp. 2838–2845, 2007.

[163] C. U. Louis, K. Straathof, C. M. Bollard et al., “Adaptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma,” *Journal of Immunotherapy*, vol. 33, no. 9, pp. 983–990, 2010.

[164] V. P. Lutzky, J. E. Davis, P. Crooks et al., “Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients,” *Immunology and Cell Biology*, vol. 87, no. 6, pp. 481–488, 2009.

[165] C. U. Louis, K. Straath, C. M. Bollard et al., “Enhancing the in vivo expansion of adaptively transferred EBV- Specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients,” *Blood*, vol. 113, no. 11, pp. 2442–2450, 2009.

[166] Y. Pan, J. Zhang, L. Zhou, J. Zuo, and Y. Zeng, “In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus,” *Biochemical and Biophysical Research Communications*, vol. 347, no. 3, pp. 551–557, 2006.

[167] S. P. Lee, A. T. C. Chan, S. T. Cheung et al., “CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells,” *Journal of Immunology*, vol. 165, no. 1, pp. 573–582, 2000.

[168] D. Martorelli, K. Houali, L. Caggiari et al., “Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy,” *International Journal of Cancer*, vol. 123, no. 5, pp. 1100–1107, 2008.

[169] B. De Angelis, G. Dotti, C. Quintarelli et al., “Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506),” *Blood*, vol. 114, no. 23, pp. 4784–4791, 2009.

[170] J. Brewin, C. Mancao, K. Straathof et al., “Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease,” *Blood*, vol. 114, no. 23, pp. 4792–4803, 2009.

[171] S. A. Rosenberg, M. T. Lotze, L. M. Muul et al., “Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer,” *The New England Journal of Medicine*, vol. 313, no. 23, pp. 1485–1492, 1985.

[172] S. A. Rosenberg, M. T. Lotze, L. M. Muul et al., “A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone,” *The New England Journal of Medicine*, vol. 316, no. 15, pp. 889–897, 1987.

[173] K. Margolin, “Cytokine therapy in cancer,” *Expert Opinion on Biological Therapy*, vol. 8, no. 10, pp. 1495–1505, 2008.

[174] J. S. Miller, J. Tessmer-Tuck, B. A. Pierson et al., “Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity,” *Biology of Blood and Marrow Transplantation*, vol. 3, no. 1, pp. 34–44, 1997.

[175] K. Kalwak, M. Ussowicz, E. Gorczynska et al., “Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors,” *Journal of Interferon and Cytokine Research*, vol. 23, no. 4, pp. 173–181, 2003.

[176] D. J. Gottlieb, H. G. Prentice, A. B. Mehta et al., “Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma,” *The British Journal of Haematology*, vol. 75, no. 4, pp. 499–505, 1990.

[177] C. Frohn, M. Hoppner, P. Schlenke, H. Kirchner, P. Kortk, and J. Luhm, “Anti-myeloma activity of natural killer lymphocytes,” *The British Journal of Haematology*, vol. 119, no. 3, pp. 660–664, 2002.
[178] V. P. Khatri, R. A. Baiocchi, Z. P. Bernstein, and M. A. Caligiuri, "Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer," *Cancer Journal from Scientific American*, vol. 3, supplement 1, pp. S128–S136, 1997.

[179] Z. P. Bernstein, M. M. Porter, M. Gould et al., "Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity," *Blood*, vol. 86, no. 9, pp. 3287–3294, 1995.

[180] T. A. Waldmann, "The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design," *Nature Reviews Immunology*, vol. 6, no. 8, pp. 595–601, 2006.

[181] J. S. Miller, "Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential?" *Cytotherapy*, vol. 11, no. 3, pp. 259–260, 2009.

[182] Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato, "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 19, pp. 12293–12297, 2002.

[183] J. Liu, A. Hamrouni, D. Wolowiec et al., "Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway," *Blood*, vol. 110, no. 1, pp. 296–304, 2007.

[184] D. M. Benson Jr., C. E. Bakan, A. Mishra et al., "The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody," *Blood*, vol. 116, no. 13, pp. 2286–2294, 2010.

[185] C. Petrovas, J. P. Casazza, J. M. Brenchley et al., "PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection," *Journal of Experimental Medicine*, vol. 203, no. 10, pp. 2281–2292, 2006.

[186] T. C. Greenough, S. C. Campbellone, R. Brody et al., "Programmed death-1 expression on Epstein barr virus specific CD8+ T Cells varies by stage of infection, epitope specificity, and T-cell receptor usage," *PLoS One*, vol. 5, no. 9, Article ID e12926, 2010.

[187] A. Merlo, R. Turrini, R. Dolcetti et al., "The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders," *Haematologica*, vol. 95, no. 10, pp. 1769–1777, 2010.

[188] S. M. Amos, J. H. Pegram, J. A. Westwood et al., "Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice," *Cancer Immunology, Immunotherapy*, vol. 60, no. 5, pp. 671–683, 2011.

[189] L. Ruggeri, M. Capanni, E. Urbani et al., "Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants," *Science*, vol. 295, no. 5562, pp. 2097–2100, 2002.

[190] H. G. Klingemann, "Natural killer cell-based immunotherapy strategies," *Cytometry*, vol. 7, no. 1, pp. 16–22, 2005.

[191] H. G. Ljunggren and K. J. Malmberg, "Prospects for the use of NK cells in immunotherapy of human cancer," *Nature Reviews Immunology*, vol. 7, no. 5, pp. 329–339, 2007.

[192] L. Y. Pappworth, E. C. Wang, and M. Rowe, "The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing," *Journal of Virology*, vol. 81, no. 2, pp. 474–482, 2007.

[193] W. H. Feng, G. Hong, H. J. Delecluse, and S. C. Kenney, "Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas," *Journal of Virology*, vol. 78, no. 4, pp. 1893–1902, 2004.

[194] K. F. Hui and A. K. S. Chiang, "Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death," *International Journal of Cancer*, vol. 126, no. 10, pp. 2479–2489, 2010.

[195] C. M. Shirley, J. Chen, M. Shamay et al., "Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma," *Blood*, vol. 117, no. 23, pp. 6297–6303, 2011.

[196] S. P. Perrine, O. Hermine, T. Small et al., "A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies," *Blood*, vol. 109, no. 6, pp. 2571–2578, 2007.

[197] D. Baltimore, M. P. Boldin, R. M. O’Connell, D. S. Rao, and K. D. Taganov, "MicroRNAs: new regulators of immune cell development and function," *Nature Immunology*, vol. 9, no. 8, pp. 839–845, 2008.

[198] H. Okada, G. Kohanbash, and M. T. Lotze, "MicroRNAs in immune regulation—opportunities for cancer immunotherapy," *International Journal of Biochemistry and Cell Biology*, vol. 42, no. 8, pp. 1256–1261, 2010.

[199] A. Banerjee, F. Schambach, C. S. Dejong, S. M. Hammond, and S. L. Reiner, "Micro-RNA-155 inhibits IFN-γ signaling in CD4+ T cells," *European Journal of Immunology*, vol. 40, no. 1, pp. 225–231, 2010.

[200] Q. J. Li, J. Chau, P. J. R. Ebert et al., "miR-181a is an intrinsic modulator of T cell sensitivity and selection," *Cell*, vol. 129, no. 1, pp. 147–161, 2007.

[201] T. A. Fehniger, T. Wylie, E. Germino et al., "Next-generation sequencing identifies the natural killer cell microRNA transcriptome," *Genome Research*, vol. 20, no. 11, pp. 1590–1604, 2010.

[202] N. A. Bezman, E. Cedars, D. F. Steiner, R. Blelloch, D. G. T. Heskelle, and L. L. Lanier, "Distinct requirements of microRNAs in NK cell activation, survival, and function," *Journal of Immunology*, vol. 185, no. 7, pp. 3835–3846, 2010.

[203] A. L. Ellis-Connell, T. Iempridee, I. Xu, and J. E. Mertz, "Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death," *Journal of Virology*, vol. 84, no. 19, pp. 10329–10343, 2010.
Author/s: 
Martorelli, D; Muraro, E; Merlo, A; Turrini, R; Fae, DA; Rosato, A; Dolcetti, R

Title: 
Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders

Date: 
2012-01-01

Citation: 
Martorelli, D., Muraro, E., Merlo, A., Turrini, R., Fae, D. A., Rosato, A. & Dolcetti, R. (2012). Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders. CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012, https://doi.org/10.1155/2012/931952.

Persistent Link: 
http://hdl.handle.net/11343/272169

File Description: 
Published version

License: 
CC BY